RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • Rewriting Faulty RNA
    When Daniel de Boer’s son was diagnosed with Cystic Fibrosis, the serial entrepreneur gathered a group of biotech experts to pursue a new approach to treating rare diseases. His company ProQR is developing a platform for correcting faulty RNA that underlie specific rare diseases. We spoke to de Boer about how he came to launch ProQR, the company’s platform technology, and why the approach may be able to address a broad range of diseases.
    18 min
  • Experimental Drug for "Elephant Man" Disease May Benefit Certain Cancers Too
    Joseph Merrick, who was known as the Elephant Man, suffered from Proteus syndrome, a rare disorder that causes abnormal and disproportionate overgrowth of the skeleton, skin, adipose tissue, and central nervous system. ArQule is developing a treatment for Proteus syndrome and other overgrowth disorders. We spoke to Brian Schwartz, chief medical officer of ArQule, about its potential treatment for Proteus syndrome, how it works, and why it may have implications in a number of other indications including several forms of cancer.
    22 min
  • Programming Stem Cells to Protect Neurons in ALS and other Neurodegenerative Conditions
    BrainStorm Cell Therapeutics is developing autologous stem cell therapies for debilitating neurodegenerative diseases such as ALS. Its platform technology induces mesenchymal stem cells to secrete high levels of neuro-protective factors that promote the survival of neurons. We spoke to Chaim Lebovits, CEO of BrainStorm, about ALS, the company’s platform technology, how the company’s approach may be able to address a range of neurodegenerative diseases.
    18 min
  • Why a Topical, Off-the-Shelf, Gene Therapy May Hold Promise for a Rare Skin Condition
    Dystrophic epidermolysis bullosa is a rare genetic disease that affects the skin and other organs. People with the condition have skin that is so fragile that minor trauma can cause blistering and wounds. It is a painful condition and can have fatal consequences. Krystal Biotech is developing a gene therapy delivered as a topical gel for DEB and other skin conditions. We spoke to Krish Krishnan, CEO of Krystal Biotech, about the company’s gene therapy platform, why it uses the herpes simplex virus as a vector, and how its off-the-shelf gene therapy works.
    26 min
  • An Ironman Champion with Cystic Fibrosis Discusses her Changing Relationship with Her Disease
    Lisa Bentley spent 20 years competing as a professional athlete, although early in her career she kept secret that she suffered from the rare lung disease cystic fibrosis. Despite her medical condition, Bentley won 11 Ironman races and 11 half Ironman races, had several top five finishes at the Ironman World Championships, and represented Canada on multiple national teams and at the Pan American Games. We spoke to Bentley about her new book An Unlikely Champion, why she eventually went public about her condition, and why she considers having CF a gift.
    36 min
  • Why an Experimental Fragile X Drug May Treat a Range of Neurodegenerative Diseases
    Fragile X Syndrome is a rare developmental disorder and the most common cause of inherited intellectual disability. Tetra Discovery Partners, building on research about the role the enzyme PDE4 plays in the disease, is developing an experimental drug to inhibit its activity. We spoke to Mark Gurney, chairman and CEO of Tetra Discovery Partners, about Fragile X, the potential of its PDE4 inhibitor, and why this drug may have therapeutic benefit in a range of neurodegenerative diseases.
    24 min
  • The Case for a Daily Self-Injection to Treat Hemophilia
    The treatment of hemophilia has been moving toward longer periods between the dosing of recombinant factors. Now, with the advent of gene therapies, the potential of a one-time curative treatment appears to be on the horizon. But Catalyst Biosciences believes it can improve care for patients with the rare bleeding disorder with a daily self-injection. We spoke to Nassim Usman, CEO of Catalyst, about the company’s approach to hemophilia, how its drugs work, and why he believes his company’s pipeline may provide better alternatives for hemophilia patients.
    24 min
  • Addressing the Challenges of R&D for Rare Cancer Therapies
    Rare cancers, like other rare diseases, face the challenges of mustering research attention, access to patients and biological materials, and generating the interest of drug developers. Nevertheless, as a group, rare cancers are the leading cause of cancer deaths in the United States. The Rare Cancer Research Foundation is seeking to change the research and development landscape in rare cancer by bringing together patient organizations and researchers and building the necessary pieces needed to advance research and the development of therapeutics. We spoke to Barbara Van Hare, Director of Foundation Partnerships at The Rare Cancer Research Foundation, about the rare cancer landscape, how the foundation is forging collaborations between patient groups and researchers, and how its Pattern.org project is developing a crucial source of biological samples to advance research.
    22 min
  • Learning to Communicate and Collaborate as a Patient Advocate
    In August 2016, Luke Rosen’s two-year old daughter, Susannah, was diagnosed with a rare, neurodegenerative disease called KIF1A Associated Neurological Disorder. At the time, she was one of only about 15 people known to have the condition. Ahead of the upcoming RARE Patient Advocacy Symposium hosted Saturday, May 19 by Global Genes, in partnership with the Penn Medicine Orphan Disease Center at the University of Pennsylvania's Perelman School of Medicine, we spoke to Rosen about his journey as a patient advocate, how he has sought to build an organization to advance research into his daughter’s condition, and his work now as a patient advocate within a biotech company.
    28 min
  • Seeking Answers for Undiagnosed Patients
    For patients with a rare disease, the diagnostic odyssey can be a long journey fraught with many wrong answers. The Undiagnosed Diseases Network is a research study funded by the National Institutes of Health to bring together clinical researchers from across the country armed with advanced technologies to solve the most vexing cases. Ahead of Undiagnosed Disease Day on April 29, we spoke to Kimberly LeBlanc, associate director of research operations for the Undiagnosed Diseases Network, about the challenges rare disease patients face in getting a diagnosis, how the network works, and why its work holds the potential to help clinicians better diagnose rare disease patients.
    17 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.